Evidence map›Paper›PMID 29956556›Full record

ReviewArtificial cells, nanomedicine, and biotechnology2018

Comparison of conventional and advanced in vitro models in the toxicity testing of nanoparticles.

Eleonore Fröhlich

Abstract readComparative StudyReview
In one paragraph

Review in Artificial cells, nanomedicine, and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Menadione as Antibiotic Adjuvant AgainstAntibiotics (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Safety Landscape of Therapeutic Nanozymes and Future Research Directions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  14. In vivo safety evaluation method for nanomaterials for cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Nanoparticles: Taking a Unique Position in Medicine.Nanomaterials (Basel, Switzerland) · 2023
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Eleonore Fröhlicha Center for Medical Research , Medical University of Graz , Graz , Austria.

Funding

Austrian Science Fund FWF P 22576
6 · The paper itself

Abstract

Humans are exposed to a wide variety of nanoparticles (NPs) present in the environment, in consumer, health and medical products, and in food. Conventional cytotoxicity testing compared to animal testing is less expensive, faster and avoids ethical problems at the expense of a lower predictive value. New cellular models and exposure conditions have been developed to overcome the limitations of conventional cell culture and obtain more predictive data. The use of three-dimensional culture, co-culture and inclusion of mechanical stimulation can provide physiologically more relevant culture conditions. These systems are particularly relevant for oral, respiratory and intravenous exposure to NPs and it may be assumed that physiologically relevant application of the NPs can improve the predictive value of in vitro testing. Various groups have used advanced culture and exposure systems, but few direct comparisons between data from conventional cultures and from advanced systems exist. In silico models may present another option to predict human health risk by NPs without using animal studies. In the absence of validation, the question whether these alternative models provide more predictive data than conventional testing remains elusive.

Indexed as

AnimalsCell DifferentiationHumansNanoparticlesOrgan SpecificityToxicity TestsAlternative modelsco-cultureinhalation exposureintravenous exposurenanoparticlesoral exposure

Identifiers

PMID29956556
PMCPMC6214528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.